Cambium Bio Limited is a clinical-stage regenerative medicine company based in Sydney, Australia, focusing on developing innovative biologics for ophthalmology and tissue repair applications. Their primary technology leverages human platelet lysate to create a pipeline of novel therapeutics, with a strong focus on ophthalmology.